A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs OMP 336B11 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 13 Sep 2017 According to an Oncomed media release, the first patient has been dosed in this trial. Kyriakos Papadopoulos is the lead investigator of this trial.
- 13 Sep 2017 Status changed from planning to recruiting, according to an Oncomed media release.
- 02 Aug 2017 According to a company media release, OncoMed expects to enroll the first-patient in this trial in 2H17.